Alicia M. Douglas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alicia M. Douglas has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Abdul Mannan
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
17 shared publications - Dilana E. Staudt
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
17 shared publications - Evangeline R. Jackson
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
17 shared publications - Izac J. Findlay
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
17 shared publications - Matthew D. Dun
University of Newcastle
17 shared publications - Ryan J. Duchatel
Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
17 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
All Supplementary Figures and their captions.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
Supplementary Data from ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
All Supplementary Figures and their captions.
- Open Access
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
- 14 July 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma
Supplementary Data from ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma